Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 248

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 248
---
4, OmnigenicsAI, the Parent, and MultiplAI signed a binding term sheet outlining the terms and conditions for a Reseller License Agreement to settle MultiplAI’s outstanding debt to the Parent, amounting to $395,260, due by February 2025. Under the agreement, MultiplAI will grant OmnigenicsAI exclusive rights to commercialize its proprietary blood -basedscreening tests in Latin America, along with providing 600 pre -paidtests for business development purposes. These exclusive rights are granted for a period of five years, commencing on January 1, 2025. The effects of this agreement in the pro forma financial information are as follows: (a)If this agreement had been signed on July 1, 2023, as of June 30, 2024, OmnigenicsAI would have recognized an intangible assets amortization of $31,052 disclosed in the “Selling expenses” line in the Pro forma Combined Consolidated Statement of Operations, considering a useful life of five years (see Note (2) under “ Adjustments to Unaudited Pro Forma Combined Consolidated Statement of Operations for the Year Ended June 30, 2024”). The intangible asset assumes a useful life of five years, with amortization starting in the first year; (b)as of June 30, 2024, OmnigenicsAI would have recognized an intangible assets of $155,260 in the Pro forma Combined Consolidated Statement of Financial Position, allocated entirely to the exclusive license rights; (c)this agreement would have generated a credit of $240,000 disclosed under “ Trade and other receivables, net” in the Pro forma Combined Consolidated Statement of Financial Position as of June 30, 2024, which represents the right to receive 600 pre -paidtests from MultiplAI; and (d)Considering these in -kindcontributions from the Parent to OmnigenicsAI will not imply the issuance of additional Company Shares, the counterpart of these contributed assets will be an increase in Accumulated deficit (transaction with the Parent). The figures disclosed in the Pro Forma Combined Consolidated Statement of Financial Position are based on the assumption that the values considered represent the fair values of the assets incorporated. Share Capital The composition of the share capital after giving pro forma effect to the Business Combination and in the different scenarios described are disclosed below (considering par value of $0.0001 per share):

|                                                |     |     Scenario 1